The differential response to anti IL-6 treatment in COVID-19: the genetic counterpart

Clin Exp Rheumatol. 2020 May-Jun;38(3):580. Epub 2020 May 10.

Authors

Affiliations

¹ Rheumatology Unit, Department of Medicine, University of Perugia, Italy.
² Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
³ UniCamillus, Saint Camillus International University of Health Sciences, Rome, and Department of Biomedicine and Prevention, Section of Genetics, School of Medicine, University of Rome Tor Vergata, Rome, Italy.
⁴ Department of Biomedicine and Prevention, Section of Genetics, School of Medicine, University of Rome Tor Vergata, Rome, Italy.
⁵ Rheumatology Unit, Department of Medicine, University of Perugia, Italy. roberto.gerli@unipg.it.

PMID: 32452345

No abstract available

Publication types

Letter

MeSH terms

Adaptor Proteins, Signal Transducing / genetics*
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized / therapeutic use
Antigens, CD / genetics
Antigens, Differentiation, T-Lymphocyte / genetics
Arthritis, Rheumatoid / drug therapy
Arthritis, Rheumatoid / genetics
Betacoronavirus
COVID-19
Coronavirus Infections / drug therapy*
Coronavirus Infections / genetics*
Humans
Interleukin-6 / antagonists & inhibitors*
Lectins, C-Type / genetics
Middle Aged
Pandemics
Pneumonia, Viral / drug therapy*
Pneumonia, Viral / genetics*
Polymorphism, Single Nucleotide
Receptors, Interleukin-6 / genetics
SARS-CoV-2

Substances

Adaptor Proteins, Signal Transducing
Antibodies, Monoclonal, Humanized
Antigens, CD
Antigens, Differentiation, T-Lymphocyte
CD69 antigen
IL6 protein, human
IL6R protein, human
Interleukin-6
Lectins, C-Type
Receptors, Interleukin-6
TRAF3IP2 protein, human
tocilizumab